From the *Departments of Medicine, University of Rochester/Strong Memorial Hospital, Rochester, NY; and †New York Medical College/Westchester Medical Center, Valhalla, NY.
Cardiol Rev. 2017 Nov/Dec;25(6):315-320. doi: 10.1097/CRD.0000000000000169.
Numerous investigators have attempted to target the natriuretic peptide system in the treatment of heart failure since it was first described over 30 years ago. The history of neprilysin inhibition as a treatment for heart failure has been characterized by numerous setbacks. Recently, the PARADIGM-HF trial has shown favorable results, which may bring neprilysin inhibition into the mainstream of clinical practice. This article will review the history of the natriuretic peptide system and the investigations into it as a target for heart failure treatment, culminating in the positive results of the PARADIGM-HF trial, as well as planned and potential future directions for research.
自 30 多年前首次描述以来，许多研究人员试图针对利钠肽系统来治疗心力衰竭。肾素抑制剂治疗心力衰竭的历史充满了无数挫折。最近，PARADIGM-HF 试验取得了有利结果，这可能使肾素抑制剂成为临床实践的主流。本文将回顾利钠肽系统的历史及其作为心力衰竭治疗靶点的研究，最终介绍 PARADIGM-HF 试验的积极结果，以及计划和潜在的未来研究方向。
